465
Participants
Start Date
October 13, 2020
Primary Completion Date
October 1, 2023
Study Completion Date
October 1, 2023
clonoSEQ Assay
minimal residual disease (MRD) assay using blood, bone marrow, or other tissue containing tumor cells
Hospital of the University of Pennsylvania, Philadelphia
Georgetown University, Washington D.C.
American Oncology Partners of Maryland, Bethesda
Novant Health, Charlotte
Bon Secours St Francis, Greenville
Holy Cross Hospital, Fort Lauderdale
Edward H. Kaplan MD & Associates, Skokie
Washington University, St Louis
Hematology Oncology Clinic, Baton Rouge
Stanford Hospital, Stanford
Oregon Health & Science University, Knight Cancer Institute, Portland
University of Washington, Seattle Cancer Care Alliance, Seattle
Swedish Cancer Institute, Seattle
Northwest Medical Specialties, Tacoma
Lead Sponsor
Adaptive Biotechnologies
INDUSTRY